Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Tomi LazarovImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-6312-0080
Pierre-Louis LoyherImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hairu YangImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Zi-Ning ChooTri-Institutional MD-PhD Program, Weill Cornell Medicine, New York, NY 10065, USA.
Zihou DengImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0007-2743-668X
Sonja NowotschinDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-2646-8598
Ying-Yi KuoDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-1962-5559
Ting ZhouSKI Stem Cell Research Core, Memorial Sloan Kettering Cancer Center, NY, New York 10065, USA.ORCID 0000-0003-1423-1507
Araitz Alberdi-GonzalezImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3078-9121
Ralf StummInstitute for Pharmacology/Toxicology, Jena University Hospital, D-07747 Jena, Germany.
Elvira MassDevelopmental Biology of the Immune System, Life & Medical Sciences (LIMES) Institute, University of Bonn, 53115 Bonn, Germany.ORCID 0000-0003-2318-2356
Elisa Gomez PerdigueroInstitut Pasteur, Macrophages and Endothelial cells Unit, Department of Developmental and Stem Cell Biology, UMR3738 CNRS, F-75015 Paris, France.ORCID 0000-0002-7717-7897
Anna-Katerina HadjantonakisDevelopmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7580-5124
Frederic GeissmannImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-5029-2468
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Macrophage development and specification in mice.R01AI130345 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Frederic Geissmann · 2017 to 2026
$5.7M
Role of Microglia Somatic Variants in Neurodegenerative DiseasesR01NS115715 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI GEISSMANN, FREDERIC · 2019 to 2023
$5.0M
Phenotyping Early Embryonic Lethal Knockout Mice to Identify Essential Genes with Previously Uncharacterized Roles in Pre-implantation Development, Gastrulation, Turning, and PlacentationR01HD086478 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI HADJANTONAKIS, ANNA-KATERINA · 2016 to 2020
$3.4M
The gut endoderm: origin, formation and fateR01DK127821 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI ANNA-KATERINA HADJANTONAKIS · 2021 to 2026
$3.4M
Lineages and pathophysiology of clonal histiocytic disordersR01HL138090 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI GEISSMANN, FREDERIC · 2017 to 2020
Mammalian hematopoietic cells arise from mesodermal progenitors in a close developmental relationship with endothelium and along three distinct cell lineages known as primitive, prodefinitive, and definitive hematopoiesis. However, the developmental hierarchies between early mesodermal progenitors, endothelium, and blood cell lineages are incompletely understood. Here, fate-mapping, cloning, and genetic experiments identified a population of KDR
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Characterization of the mammalian prodefinitive angio-hematopoietic lineage. · full record | OpenQuestion